| 1 |
Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet. 1978; 1: 263. PubMed |
| 2 |
Grüntzig AR, et al. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979; 301: 61-8. PubMed |
| 3 |
de Feyter PJ, et al. Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. Am Heart J. 1994; 127: 643-51. PubMed |
| 4 |
Nobuyoshi M, et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol. 1988; 12: 616-23. PubMed |
| 5 |
Nobuyoshi M, et al. Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients. J Am Coll Cardiol. 1991; 17: 433-9. PubMed |
| 6 |
Sigwart U, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987; 316: 701-6. PubMed |
| 7 |
Serruys PW, et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med. 1991; 324: 13-7. PubMed |
| 8 |
Schömig A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996; 334: 1084-9. PubMed |
| 9 |
Cutlip DE, et al. Acute and nine-month clinical outcomes after "suboptimal" coronary stenting: results from the stent anti-thrombotic regimen study (STARS) registry. J Am Coll Cardiol. 1999; 34: 698-706. PubMed |
| 10 |
Colombo A, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 1995; 91: 1676-88. PubMed |
| 11 |
Fischman DL, et al.; Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994; 331: 496-501. PubMed |
| 12 |
Serruys PW, et al.; Benestent Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994; 331: 489-95. PubMed |
| 13 |
Gordon PC, et al. Mechanisms of restenosis and redilation within coronary stents--quantitative angiographic assessment. J Am Coll Cardiol. 1993; 21: 1166-74. PubMed |
| 14 |
Hoffmann R, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation. 1996; 94: 1247-54. PubMed |
| 15 |
Sousa JE, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2001; 103: 192-5. PubMed |
| 16 |
Sousa JE, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001; 104: 2007-11. PubMed |
| 17 |
Morice MC, et al.; RAVEL Study Group. Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346: 1773-80. PubMed |
| 18 |
Moses JW, et al.; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349: 1315-23. PubMed |
| 19 |
Weisz G, et al. Two-year outcomes after sirolimus-eluting stent implantation: results from the sirolimus-eluting stent in de novo native coronary lesions (SIRIUS) trial. J Am Coll Cardiol. 2006; 47: 1350-5. PubMed |
| 20 |
Weisz G, et al. Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (sirolimus-eluting stent in de-novo native coronary lesions) trial. J Am Coll Cardiol. 2009; 53: 1488-97. PubMed |
| 21 |
Sabaté M, et al.; DIABETES Investigators. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation. 2005; 112: 2175-83. PubMed |
| 22 |
Spaulding C, et al.; TYPHOON Investigators. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med. 2006; 355: 1093-104. PubMed |
| 23 |
Suttorp MJ, et al. Primary stenting of totally occluded native coronary arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation. 2006; 114: 921-8. PubMed |
| 24 |
Vermeersch P, et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC trial. J Am Coll Cardiol. 2006; 48: 2423-31. PubMed |
| 25 |
Ardissino D, et al.; SES-SMART Investigators. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA. 2004; 292: 2727-34. PubMed |
| 26 |
Menozzi A, et al.; SES-SMART Investigators. Twenty-four months clinical outcomes of sirolimus-eluting stents for the treatment of small coronary arteries: the long-term SES-SMART clinical study. Eur Heart J. 2009; 30: 2095-101. PubMed |
| 27 |
Kelbaek H, et al.; SCANDSTENT Investigators. The stenting coronary arteries in non-stress/benestent disease (SCANDSTENT) trial. J Am Coll Cardiol. 2006; 47: 449-55. PubMed |
| 28 |
Kelbaek H, et al. Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (stenting coronary arteries in non-stress/benestent disease) trial. J Am Coll Cardiol. 2008; 51: 2011-6. PubMed |
| 29 |
Grube E, et al. TAXUS I: Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003; 107: 38-42. PubMed |
| 30 |
Silber S, et al. Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions. Circulation. 2009; 120: 1498-504. PubMed |
| 31 |
Serruys PW, et al. Arterial revascularisation therapies study part II - sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. EuroIntervention. 2005; 1: 147-56. PubMed |
| 32 |
Serruys PW, et al.; Arterial Revascularization Therapies Study Group. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 2001; 344: 1117-24. PubMed |
| 33 |
McFadden EP, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004; 364: 1519-21. PubMed |
| 34 |
Liistro F, et al. Late acute thrombosis after paclitaxel eluting stent implantation. Heart. 2001; 86: 262-4. PubMed |
| 35 |
Kerner A, et al. Late stent thrombosis after implantation of a sirolimus-eluting stent. Catheter Cardiovasc Interv. 2003; 60: 505-8. PubMed |
| 36 |
Serruys PW, et al. Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents. Circulation. 2007; 115: 1433-9. PubMed |
| 37 |
Daemen J, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007; 369: 667-78. PubMed |
| 38 |
James SK, et al.; Swedish Coronary Angiography and Angioplasty Registry (SCAAR) study group. The SCAAR-scare in perspective. EuroIntervention. 2009; 5: 501-4. PubMed |
| 39 |
Pinto Slottow TL, et al. Observations and outcomes of definite and probable drug-eluting stent thrombosis seen at a single hospital in a four-year period. Am J Cardiol. 2008; 102: 298-303. PubMed |
| 40 |
Lasala JM, et al. Expanded use of the TAXUS Express stent: two-year safety insights from the 7,500 patient ARRIVE Registry programme. EuroIntervention. 2009; 5: 67-77. PubMed |
| 41 |
Brodie BR, et al.; STENT (Strategic Transcatheter Evaluation of New Therapies) Group. Outcomes and complications with off-label use of drug-eluting stents: results from the STENT (Strategic Transcatheter Evaluation of New Therapies) group. JACC Cardiovasc Interv. 2008; 1: 405-14. PubMed |
| 42 |
van Werkum JW, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009; 53: 1399-409. PubMed |
| 43 |
Lasala JM, et al.; ARRIVE 1 and ARRIVE 2 Participating Physicians. Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries. Circ Cardiovasc Interv. 2009; 2: 285-93. PubMed |
| 44 |
Kimura T, et al.; RESTART Investigators. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: Observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). Circulation. 2010; 122: 52-61. PubMed |
| 45 |
Inoue K. Drug-eluting stents are not indicated for patients with acute coronary syndrome ? should drug-eluting stents be indicated for patients with acute coronary syndrome? (Con) ?. Circ J. 2010; 74: 2232-8. PubMed |
| 46 |
Nakazawa G, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation. 2008; 118: 1138-45. PubMed |
| 47 |
Virmani R, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004; 109: 701-5. PubMed |
| 48 |
Kotani J, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol. 2006; 47: 2108-11. PubMed |
| 49 |
Awata M, et al. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents. Circulation. 2007; 116: 910-6. PubMed |
| 50 |
Kozuma K, et al. Angiographic findings of stent thrombosis cases after sirolimus-eluting stent implantation. Eur Heart J. 2010; 31(Abstract Supplement): 660. ESC Congress 2010 |
| 51 |
Alfonso F, et al. Coronary aneurysms after drug-eluting stent implantation: clinical, angiographic, and intravascular ultrasound findings. J Am Coll Cardiol. 2009; 53: 2053-60. PubMed |
| 52 |
Cook S, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation. 2007; 115: 2426-34. PubMed |
| 53 |
Kedhi E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010; 375: 201-9. PubMed |
| 54 |
Chevalier B, et al.; NOBORI 1 Clinical Investigators. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2. Circ Cardiovasc Interv. 2009; 2: 188-95. PubMed |
| 55 |
Iakovou I, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005; 293: 2126-30. PubMed |
| 56 |
Spertus JA, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006; 113: 2803-9. PubMed |
| 57 |
Airoldi F, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation. 2007; 116: 745-54. PubMed |
| 58 |
Farb A, et al. Stent thrombosis redux--the FDA perspective. N Engl J Med. 2007; 356: 984-7. PubMed |
| 59 |
Schulz S, et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J. 2009; 30: 2714-21. PubMed |
| 60 |
Kimura T, et al.; j-Cypher Registry Investigators. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation. 2009; 119: 987-95. PubMed |
| 61 |
Park SJ, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med. 2010; 362: 1374-82. PubMed |
| 62 |
Trenk D, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008; 51: 1925-34. PubMed |
| 63 |
Hoshino K, et al. Clopidogrel resistance in Japanese patients scheduled for percutaneous coronary intervention. Circ J. 2009; 73: 336-42. PubMed |
| 64 |
Wiviott SD, et al.; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357: 2001-15. PubMed |
| 65 |
Nordmann AJ, et al. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J. 2006; 27: 2784-814. PubMed |
| 66 |
Pfisterer M, et al.; BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006; 48: 2584-91. PubMed |
| 67 |
Camenzind E, et al. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation. 2007; 115: 1440-55. PubMed |
| 68 |
Lagerqvist B, et al.; SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007; 356: 1009-19. PubMed |
| 69 |
Spaulding C, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007; 356: 989-97. PubMed |
| 70 |
James SK, et al.; SCAAR Study Group. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N Engl J Med. 2009; 360: 1933-45. PubMed |
| 71 |
Serruys PW, et al. The SCAAR registry or the Swedish yo-yo. EuroIntervention. 2007; 3: 297-300. PubMed |
| 72 |
Stone GW, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007; 356: 998-1008. PubMed |
| 73 |
Kastrati A, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007; 356: 1030-9. PubMed |
| 74 |
Mauri L, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007; 356: 1020-9. PubMed |
| 75 |
Douglas PS, et al. Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry. J Am Coll Cardiol. 2009; 53: 1629-41. PubMed |
| 76 |
Kirtane AJ, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009; 119: 3198-206. PubMed |
| 77 |
Toyofuku M, et al.; j-Cypher Registry Investigators. Three-year outcomes after sirolimus-eluting stent implantation for unprotected left main coronary artery disease: insights from the j-Cypher Registry. Circulation. 2009; 120: 1866-74. PubMed |
| 78 |
Abe M, et al.; j-Cypher Registry Investigators. Sirolimus-eluting stent versus balloon angioplasty for sirolimus-eluting stent restenosis: Insights from the j-Cypher Registry. Circulation. 2010; 122: 42-51. PubMed |
| 79 |
Kimura T, et al.; j-Cypher Registry Investigators: Incidence and outcome of surgical procedures after sirolimuseluting stent implantation: a report from the j-Cypher Registry. Cardiovasc Interv and Ther. 2010; 25: 29-39. dx.doi.org/10.1007/s12928-009-0005-4 |
| 80 |
Shirai S, et al.; j-Cypher Registry Investigators. Impact of multiple and long sirolimus-eluting stent implantation on 3-year clinical outcomes in the j-Cypher Registry. JACC Cardiovasc Interv. 2010; 3: 180-8. PubMed |
| 81 |
Nakagawa Y, et al.; j-Cypher Registry Investigators. Incidence and risk factors of late target lesion revascularization after sirolimus-eluting stent implantation (3-year follow-up of the j-Cypher Registry). Am J Cardiol. 2010; 106: 329-36. PubMed |
| 82 |
Kawaguchi R, et al.; j-Cypher Registry Investigators. Safety and efficacy of sirolimus-eluting stent implantation in patients with acute coronary syndrome in the real world. Am J Cardiol. 2010; 106: 1550-60. PubMed |
| 83 |
Ozasa N, et al.; j-Cypher Registry Investigators. Lack of effect of oral beta-blocker therapy at discharge on long-term clinical outcomes of ST-segment elevation acute myocardial infarction after primary percutaneous coronary intervention. Am J Cardiol. 2010; 106: 1225-33. PubMed |
